AMG 595, an anti-EGFRvIII antibody-drug conjugate, induces potent antitumor activity against EGFRvIII-expressing glioblastoma

Molecular Cancer Therapeutics

Volumn 14, Issue 7, 2015, Pages 1614-1624

  Hamblett, Kevin J ^a   Kozlosky, Carl J ^a   Siu, Sophia ^a   Chang, Wesley S ^b   Liu, Hua ^a   Foltz, Ian N ^b   Trueblood, Esther S ^a   Meininger, David ^a   Arora, Taruna ^b,c   Twomey, Brian ^b   Vonderfecht, Steven L ^b   Chen, Qing ^b   Hill, John S ^b   Fanslow, William C ^a  

^a AMGEN INC   (United States)

^b AMGEN INC   (United States)

^c NGM Biopharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMG 595; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; HISTONE H3; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; EPIDERMAL GROWTH FACTOR RECEPTOR; MAYTANSINE; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL GROWTH; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG CONJUGATION; FEMALE; GLIOBLASTOMA; GROWTH INHIBITION; HISTONE PHOSPHORYLATION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INTERNALIZATION; MITOSIS INHIBITION; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VOLUME; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN NEOPLASMS; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; GENETICS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MUTATION; NUDE MOUSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCID MOUSE; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOCONJUGATES; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAVENOUS; MAYTANSINE; MICE, NUDE; MICE, SCID; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84942115104     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-1078     Document Type: Article

References (47)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
2. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapywith concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-66.
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
4. Moustakas A, Kreisl TN. New treatment options in the management of glioblastoma multiforme: a focus on bevacizumab. OncoTargets Ther 2010;3:27-38.
5. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17:98-110.
6. O'Dwyer PJ, Benson AB 3rd. Epidermal growth factor receptor-targeted therapy in colorectal cancer. Semin Oncol 2002;29:10-7.
7. Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 2006;24:2666-72.
8. Bigner SH, Burger PC, Wong AJ, Werner MH, Hamilton SR, Muhlbaier LH, et al. Gene amplification in malignant human gliomas: clinical and histopathologic aspects. J Neuropathol Exp Neurol 1988;47:191-205.
9. Jeuken J, Sijben A, Alenda C, Rijntjes J, Dekkers M, Boots-Sprenger S, et al. Robust detection of EGFR copy number changes and EGFR variant III: technical aspects and relevance for glioma diagnostics. Brain Pathol 2009;19:661-71.
10. Weller M, Kaulich K, Hentschel B, Felsberg J, Gramatzki D, Pietsch T, et al. Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy. Int J Cancer 2014;134:2437-47.
11. Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS, et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci U S A 1992;89:2965-9.
12. Nicholas MK, Lukas RV, Jafri NF, Faoro L, Salgia R. Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas. Clin Cancer Res 2006;12:7261-70.
13. Pedersen MW, Meltorn M, Damstrup L, Poulsen HS. The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. Ann Oncol 2001;12:745-60.
14. Wikstrand CJ, Reist CJ, Archer GE, Zalutsky MR, Bigner DD. The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. J Neurovirol 1998;4:148-58.
15. Biernat W, Huang H, Yokoo H, Kleihues P, Ohgaki H. Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas. Brain Pathol 2004;14:131-6.
16. Wikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, Kurpad SN, et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 1995;55:3140-8.
17. Yoshimoto K, Dang J, Zhu S, Nathanson D, Huang T, Dumont R, et al. Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples. Clin Cancer Res 2008;14:488-93.
18. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005;353:2012-24.
19. Del Vecchio CA, Li G, Wong AJ. Targeting EGF receptor variant III: tumorspecific peptide vaccination for malignant gliomas. Expert Rev Vaccines 2012;11:133-44.
20. Scott AM, Lee FT, Tebbutt N, Herbertson R, Gill SS, Liu Z, et al. A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci U S A 2007;104:4071-6.
21. Niwa R, SakuradaM, Kobayashi Y, Uehara A, Matsushima K, Ueda R, et al. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density. Clin Cancer Res 2005;11:2327-36.
22. Molhoj M, Crommer S, Brischwein K, Rau D, Sriskandarajah M, Hoffmann P, et al. CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis. Mol Immunol 2007;44:1935-43.
23. Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol 2010;14:529-37.
24. Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 2012;30:631-7.
25. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367:1783-91.
26. Bigner SH, Humphrey PA, Wong AJ, Vogelstein B, Mark J, Friedman HS, et al. Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res 1990;50:8017-22.
27. Pandita A, Aldape KD, ZadehG, Guha A, James CD. Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR. Genes Chromosomes Cancer 2004;39:29-36.
28. Mendez MJ, Green LL, Corvalan JR, Jia XC, Maynard-Currie CE, Yang XD, et al. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response inmice. Nat Genet 1997;15:146-56.
29. Babcook JS, Leslie KB, Olsen OA, Salmon RA, Schrader JW. A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities. Proc Natl Acad Sci U S A 1996;93:7843-8.
30. Chari RV, Martell BA, Gross JL, Cook SB, Shah SA, Blattler WA, et al. Immunoconjugates containing novel maytansinoids: promising anticancer drugs. Cancer Res 1992;52:127-31.
31. Polson AG, Yu SF, Elkins K, Zheng B, Clark S, Ingle GS, et al. Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma. Blood 2007;110:616-23.
32. Cloughesy TF, Cavenee WK, Mischel PS. Glioblastoma: from molecular pathology to targeted treatment. Annu Rev Pathol 2014;9:1-25.
33. Olar A, Aldape KD. Using the molecular classification of glioblastoma to inform personalized treatment. J Pathol 2014;232:165-77.
34. Polson AG, Calemine-Fenaux J, Chan P, Chang W, Christensen E, Clark S, et al. Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. Cancer Res 2009;69:2358-64.
35. Law CL, Gordon KA, Toki BE, Yamane AK, Hering MA, Cerveny CG, et al. Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates. Cancer Res 2006;66:2328-37.
36. Sutherland MS, Sanderson RJ, Gordon KA, Andreyka J, Cerveny CG, Yu C, et al. Lysosomal trafficking and cysteine protease metabolism confer targetspecific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J Biol Chem 2006;281:10540-7.
37. Erickson HK, Park PU, Widdison WC, Kovtun YV, Garrett LM, Hoffman K, et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 2006;66:4426-33.
38. Kovtun YV, Audette CA, Ye Y, Xie H, Ruberti MF, Phinney SJ, et al. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res 2006;66:3214-21.
39. Juan G, Traganos F, James WM, Ray JM, Roberge M, Sauve DM, et al. Histone H3 phosphorylation and expression of cyclins A and B1measured in individual cells during their progression through G2 and mitosis. Cytometry 1998;32:71-7.
40. Dittrich C, Fridrik MA, Koenigsberg R, Lee C, Goeldner RG, Hilbert J, et al. A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors. Investigational New Drugs 2015;33:409-22.
41. Moreno L, Marshall LV, Pearson AD, Morland B, Elliott M, Campbell-Hewson Q, et al. A phase I trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in children and adolescents with solid tumors: A Cancer Research UK Study. Clin Cancer Res 2015;21:267-73.
42. Mullard A. Maturing antibody-drug conjugate pipeline hits 30. Nat Rev Drug Discov 2013;12:329-32.
43. Stathis A, Freedman AS, Flinn IW, Maddocks KJ, Weitman S, Berdeja JG, et al. A phase I study of IMGN529, an antibody-drug conjugate (ADC) targeting CD37, in adult patients with relapsed or refractory B-cell Non-Hodgkin's Lymphoma (NHL). Blood 2014;124:1760.
44. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008;68:9280-90.
45. Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, Friedman HS, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 2010;28:4722-9.
46. Grossman SA, Batara JF. Current management of glioblastoma multiforme. Semin Oncol 2004;31:635-44.
47. Santostefano M, Engwall M, Everds N, Guzman R, Chow V, Upreti V, et al. AMG 595: a novel ADC with therapeutic potential in glioblastoma. 35th Annual Meeting of the American College of Toxicology Program; 2014; Orlando, FL.